Position of the Transparency Council – Ayvakyt (avapritinib)
At its meeting on 5 August 2024, the Transparency Council adopted position No. 79/2024 on the evaluation of the drug Ayvakyt (avapritinib) under the drug program: “Treatment of patients with advanced forms of systemic mastocytosis (ICD-10: C96.2, C94.3, D47.9)”
Publication of the position >>